Insights+: Key Takeaways of J.P. Morgan Healthcare Conference 2023 Based on Therapeutic Areas

Shots: The 41st Annual J.P. Morgan Healthcare Conference took place on 09 – 12 January 2023 in San Francisco, CA, USA. It is the largest and most informative healthcare investment symposium in the industry, bringing together a cohort of industry leaders, emerging fast-growing companies, innovative technology creators, and members of the investment community The major announcement…

BySenior EditorJanuary 19, 2023

INSIGHTS+

Top Performing Drug of 2021 – Eliquis (July Edition)

Active Ingredients: Apixaban Strength: 2.5 mg and 5 mg Dosage Form: Tablet Mechanism of Action: Factor Xa inhibitors First Approval: US (Dec 28, 2012), EU (May 18, 2011) Revenue1 Eliquis is a leading novel oral anticoagulant of BMS. The revenue for BMS continued to grow due to Eliquis and other recently launched new products. BMS and Pfizer jointly develop and…

BySenior EditorJuly 28, 2022

INSIGHTS+

Top Performing Drug of 2021 – Revlimid (June Edition)

Active Ingredients: Lenalidomide Strength: 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg Dosage Form: Capsules Mechanism of Action: Angiogenic inhibitor First Approval: US (Dec 27, 2005), EU (14 Jun, 2007) Revenue Revlimid (lenalidomide) is one of the key products of Bristol-Myers Squibb (BMS) that represent a significant percentage of the company’s total revenue. Sales of…

BySenior EditorJune 23, 2022

TOP 20

Top 20 BioPharma Companies based on 2021 Total Revenue

While the COVID-19 pandemic has dominated the healthcare space for the last two years, some biopharma companies were involved in multiple deals, M&A, and the development of various drug candidates in other areas to diversify their portfolios While top Biopharma companies remain on the chart, however, in 2021, new players like Moderna, BioNTech, Viatris also…

ByPrince GiriApril 14, 2022

TOP 20

Top 20 Biopharma Deal Terminations of 2021 Based on Total Deal Value

Shots: The biopharma industry saw numerous deal terminations in 2021. Clinical and regulatory results, change of control limitations, and strategic reprioritizations were among the most common reasons for deal termination. SOBI and Advent's acquisition agreement in 2021 ranked first under which Advent International offered to acquire SOBI. The second position goes to Galapagos’ development and…

ByPrince GiriMarch 10, 2022

TOP 20

Top 20 Life Sciences Deals of 2021 by Total Deal Value

Shots: The life science industry saw high deal activity in 2021 staying in the range of an even busier 2020. Fourth-quarter 2021 set the tone with Recursion’s development and commercialization deal with Roche and Genentech for a total value of $12.7B, followed by Poseida Therapeutics’ development and commercialization deal with Takeda for $3.73B. This article is based on the 2021…

ByPrince GiriFebruary 10, 2022

Insights+: Key Takeaways of J.P. Morgan Healthcare Conference 2023 Based on Therapeutic Areas

Top Performing Drug of 2021 – Eliquis (July Edition)

Top Performing Drug of 2021 – Revlimid (June Edition)

Top 20 BioPharma Companies based on 2021 Total Revenue

Top 20 Biopharma Deal Terminations of 2021 Based on Total Deal Value

Top 20 Life Sciences Deals of 2021 by Total Deal Value

Contact US

OUR INFORMATION

FOLLW US

Insights+: Key Takeaways of J.P. Morgan Healthcare Conference 2023 Based on Therapeutic Areas

Top Performing Drug of 2021 – Eliquis (July Edition)

Top Performing Drug of 2021 – Revlimid (June Edition)

Top 20 BioPharma Companies based on 2021 Total Revenue

Top 20 Biopharma Deal Terminations of 2021 Based on Total Deal Value

Top 20 Life Sciences Deals of 2021 by Total Deal Value

FOLLW US

Sign Up to Our Newsletter